Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Hodi, F. Stephen, O’Day, Steven J., McDermott, David F., Weber, Robert W., Sosman, Jeffrey A., Haanen, John B., Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C., Akerley, Wallace, van den Eertwegh, Alfons J.M., Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M., Linette, Gerald P., Hogg, David, Ottensmeier, Christian H., Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I., Wolchok, Jedd D., Weber, Jeffrey S., Tian, Jason, Yellin, Michael J., Nichol, Geoffrey M., Hoos, Axel, Urba, Walter J.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2010
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549297/
https://ncbi.nlm.nih.gov/pubmed/20525992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1003466
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים